Abstract-Hypercholesterolemia is associated with increased circulating and tissue endothelin-1 immunoreactivity, decreased nitric oxide (NO) activity, and altered endothelial function. We tested the hypothesis that chronic endothelin receptor antagonism preserves endothelial function and increases NO in experimental porcine hypercholesterolemia. Pigs were randomized to 3 groups: Group 1, a 2% high-cholesterol (HC) diet alone (nϭ7); group 2, RO-48-5695, a combined endothelin receptor antagonist, and an HC diet (nϭ8); and group 3, ABT-627, a selective endothelin-A receptor antagonist, and an HC diet (nϭ8). Coronary epicardial and arteriolar endothelial function was determined by a dose-response relaxation to bradykinin (10 Ϫ11 to 10 Ϫ6 mol/L), in all groups and in pigs maintained on a normal diet. Plasma total oxidized products of NO (NO x ) were determined by chemiluminescence at baseline and after 12 weeks. Bradykinin-stimulated coronary epicardial and arteriolar relaxation in group 1 was attenuated compared with normal-diet controls. This relaxation was normalized with endothelin receptor antagonism. Plasma NO x decreased after 12 weeks in group 1 (Ϫ74.8Ϯ5.5%). This decrease was attenuated in the endothelin receptor antagonist groups (group 2, Ϫ28.2Ϯ15.0%; group 3, Ϫ38.9Ϯ20.6%). Chronic endothelin receptor antagonism preserves coronary endothelial function and increases NO in hypercholesterolemia. This study supports a role of endothelin-1 in the regulation of NO activity and suggests a possible therapeutic role for endothelin receptor antagonists in hypercholesterolemia.
ndothelin-1 is a 21-amino acid peptide that is atherogenic and has both mitogenic and vasoconstricting properties. [1] [2] [3] These effects are exerted through the 2 endothelin receptors: the endothelin-A (ET-A) receptor located on vascular smooth muscle cells, and the endothelin-B (ET-B) receptor, located on both endothelial and vascular smooth muscle cells. 4, 5 Both receptors may mediate enhanced coronary vasoconstriction to endothelin-1 in pathophysiological states such as experimental hypercholesterolemia, in which levels of coronary tissue and circulating endothelin-1 are increased. 6 -8 Besides enhanced endothelin-1 activity, hypercholesterolemia is associated with abnormal coronary endothelial function, decreased basal nitric oxide (NO) activity, and decreased coronary endothelial cell NO synthase (NOS). 6, 9 Attenuation in NO activity is functionally important, since NO contributes to both basal and demand-mediated coronary blood flow, antagonizes the vascular effects of endothelin-1, and is intimately linked to the regulation of endothelin-1 production. 10, 11 Experimental hypercholesterolemia is also associated with increased production of oxygen free radicals and increased oxidative stress. 12, 13 This may subsequently lead to altered bioavailability of NO or functional changes of the endothelium and has important implications in the pathogenesis of atherosclerosis. 14 -16 Oxidative stress also increases endothelin-1 production and release from endothelial cells in vitro. 17, 18 Additionally, endothelin-1 may increase oxidative stress by increasing oxygen free-radical formation from macrophages. 19 Therefore, the current investigation was undertaken with the objectives to determine (1) whether chronic endothelin receptor antagonism in hypercholesterolemia preserves coronary epicardial and arteriolar endothelial function in vitro, (2) whether chronic endothelin receptor antagonism attenuates the reduction in plasma total oxidized products of NO (NO x ) and coronary endothelial NOS immunostaining associated with hypercholesterolemia, and (3) whether chronic endothelin receptor antagonism decreases plasma F 2 -isoprostane levels, an in vivo marker of oxidative stress, in experimental hypercholesterolemia.
and were designed in accordance with National Institutes of Health guidelines. Female juvenile, domestic, crossbred pigs (23 to 35 kg) (Larson Farms, Seargent, Minn) were placed on an atherogenic diet of 2% cholesterol and 15% lard by weight (TD 93296, Harlan Teklad) for 12 weeks. 8, 9 In the interim, group 1 animals (control group) did not receive any additional medications. Group 2 animals were placed on oral RO-48-5695 (Hoffmann-La Roche Ltd, Basel, Switzerland), a combined ET-A and ET-B receptor antagonist, on a weight-adjusted scale every 3 weeks to maintain the dose at 3 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 . 20 The dosage of RO-48-5695 was determined on the basis of preliminary studies by Hoffmann-La Roche. Group 3 animals (nϭ8) were placed on ABT-627 (Abbott Laboratories, Abbott Park, Ill) on a weight-adjusted scale to maintain a dose of 4 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 . 21 The dosage of ABT-627 was based on our previous studies. 22 At the start of the study and after 12 weeks of therapy, animals were anesthetized with ketamine and xylazine, and the external carotid artery was exposed by cutdown and cannulated with an 8F arterial sheath for blood pressure measurement. Plasma lipid profiles (Roche) were determined at baseline and after 12 weeks of the high-cholesterol diet. 23 Additionally, plasma was obtained at baseline and after 12 weeks of the high-cholesterol diet in all 3 groups for determination of plasma F 2 -isoprostanes and NO x . Euthanasia was performed by intravenous administration of 30 mg/kg pentobarbital sodium (Sleepaway, Fort Dodge Laboratories) for the in vitro studies. Additional control animals maintained on a normal diet were used for the in vitro studies to determine normal vascular reactivity for comparison with the 3 groups on the highcholesterol diet.
In Vitro Endothelial Function
After euthanasia, normal hearts as well as hearts from the experimental animals were harvested for in vitro analysis of coronary epicardial relaxation in response to bradykinin.
Epicardial Vessels
As previously described, 24 the hearts were placed into cold, modified Krebs-Ringer bicarbonate solution (control solution) of the following millimolar composition: 118.3 NaCl, 4.7 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 2.5 CaCl 2 , 25.0 NaHCO 3 , 0.016 Ca-EDTA, and 11.1 glucose. Rings of tissue 2 to 3 mm long were dissected from the left circumflex artery, transferred to organ chambers with 25 mL of control solution (37°C, pH 7.4), and oxygenated with 94% O 2 and 6% CO 2 . The tissue was suspended between 2 stirrups and connected to a strain gauge for continuous recording of isometric tension. The artery rings were equilibrated for 1 hour at a resting tension. Viability of the vessels was confirmed by a contractile response to 20 mmol/L KCl at baseline at 2, 4, and 6 g each time after the KCl had been washed out. At 6 g, all vessels were exposed to substance P (10 Ϫ6 mol/L, Sigma Chemical Co), an endothelium-dependent vasodilator, to verify the functional integrity of the vascular endothelium. All chambers were then washed out with the control solution.
After an equilibrium period of 30 minutes, the rings were precontracted with 10 Ϫ7 mol/L endothelin-1 (Phoenix Pharmaceuticals), and then the response to 10 Ϫ11 to 10 Ϫ6 mol/L bradykinin (Sigma) was recorded. Complete relaxation of each ring was obtained by exposure of the tissue to 10 Ϫ3.5 mol/L papaverine (Sigma). In preliminary experiments, 10 Ϫ7 mol/L endothelin-1 caused sustained contraction of porcine epicardial coronary arteries, and there was no difference in the contraction to endothelin-1 in any of the groups. Additionally, 10 rings from normal-diet pigs and 6 rings from group 1 pigs were preincubated with 10 Ϫ4 mol/L N G -monomethyl-L-arginine (L-NMMA, Sigma), an NOS inhibitor, for 20 minutes before preincubation with endothelin-1, followed by the dose response to cumulative concentrations of bradykinin. In 9 rings from normal-diet pigs and 7 rings from group 1 pigs, the dose response to cumulative concentrations of endothelin-1 (10 Ϫ10 to 10 Ϫ7 mol/L) was also determined.
Arterioles
Coronary vasomotor tone in the arterioles was determined by using previously described methods. 7,25 Segments 2 to 3 mm long of the secondary branch of the left circumflex artery, which were Ͻ500 m in diameter, were dissected under a dissecting microscope, transferred to an arteriograph filled with control solution oxygenated with 96% O 2 and 4% CO 2 , and then mounted onto microcannulas (Living System Instrumentation). Control solution was circulated from a 250-mL oxygenated reservoir through the arteriograph chamber at a flow rate of 12 mL/min. Temperature was continuously monitored (model 7000H, Jenco Electronics) to maintain the vessel environment at 37Ϯ0.5°C. The arteriograph was placed on the stage of an inverted microscope (Diaphot-TMD, Nikon), which had a video camera connected to the viewing tube. The signal obtained from the video image of the vessel was processed by an electronic system (Living System Instrumentation), which continuously measured and recorded the inner diameter (lumen) and wall thickness. Responses of the pressurized arteries were measured at a transmural pressure of 50 mm Hg. The vessels were precontracted with 10 Ϫ8 mol/L endothelin-1, and then the response to 10 Ϫ11 to 10 Ϫ6 mol/L bradykinin was recorded. Complete relaxation of each arteriole was obtained by exposure to 10 Ϫ4 mol/L papaverine (Sigma). Additionally, in 6 arterioles from normal-diet pigs, 10
Ϫ4 mol/L L-NMMA was added 20 minutes before the addition of endothelin-1, followed by the dose response to cumulative concentrations of bradykinin.
Plasma Total NO x
Plasma NO x levels were determined by chemiluminescence with a Sievers nitric oxide analyzer (model 280) as previously described. 26, 27 Blood samples from each group at baseline and after 12 weeks of therapy (group 1 nϭ7, group 2 nϭ8, and group 3 nϭ8) were centrifuged at 2500 rpm for 20 minutes at 10°C. The supernatant was removed and stored at Ϫ70°C. The NO assay was standardized by a calibration curve by using known concentrations of nitrate (0.01 mol/L to 100 mol/L) obtained from NaNO 3 . For each sample, 4 L of sample was placed in a reducing vessel with 5 mL of 0.1 mol/L vanadium(III)chloride, 1 mol/L HCl, and 100 L of antifoaming agent (Sievers) at 90°C. Each sample and standard were analyzed at least 3 times. The mean value was used for all subsequent analysis.
Endothelial NOS Immunostaining
Frozen sections of tissue were cut in 5-m sections and mounted on positively charged slides. The slides were dried at 37°C for 1 hour and fixed in acetone for 10 minutes at 4°C. The slides were air dried for 30 minutes. Endogenous peroxidase activity was blocked by placing the slides in 1.5% H 2 O 2 and 50% absolute methanol for 10 minutes and then rinsed. The slides were pretreated with 0.25% SDS for 10 minutes. To block nonspecific binding sites, the tissue was incubated with 5% goat serum (Dako)/PBS/Tween 20 for 10 minutes. Monoclonal antibodies to endothelial NOS (Transduction Laboratories) were then added (400 L of a 0.25 g/mL dilution) and incubated overnight at 4°C. The slides were rinsed, incubated for 30 minutes with biotinylated goat anti-mouse IgG diluted 1:400 and 2% normal swine serum, rinsed, incubated with peroxidase-labeled streptavidin diluted 1:500 for 30 minutes, and rinsed. Next, the tissue was stained for 15 minutes with 3-amino-9 ethylcarbazole solution and rinsed. To enhance nuclear detail, the slides were counterstained with hematoxylin. Three independent observers who were blinded to the different treatment groups reviewed the tissue sections. The presence of staining was quantified on the basis of a scoring system as previously described 6 : 0, no staining; 1, positive staining in Ͻ25% of the endothelial cells per slide; 2, positive staining in 25% to 75% of the endothelial cells; and 3, positive staining in Ͼ75% of the endothelial cells. The scores for each of the observers were averaged for each of the slides, and the average score for each of the groups was then calculated.
F 2 -Isoprostanes
Blood samples from 5 pigs in each of the 3 groups at baseline and after 12 weeks of therapy were collected in EDTA tubes, and the plasma was stored at Ϫ80°C until the time of the assay. The total levels of 8-isoprostaglandin F 2 were measured with an enzyme immunoassay kit (EIA, Cayman). Before the enzyme immunoassay, alkaline hydrolysis was used. 28 Plasma samples were purified by Sep-Pak C-18 columns (Waters) before analysis. The samples, tracer, and antiserum were added to wells precoated with mouse monoclonal antibody. The plates were washed to remove all unbound reagents. Ellman's reagent (containing the substrate to acetylcholinesterase) was added to the wells. The intensity of the distinct yellow color produced by this enzymatic reaction was determined with a spectrophotometer at 405 nm.
Statistical Analysis
Data are expressed as meanϮSEM. Within each group, repeated measurements were analyzed with repeated-measures ANOVA followed by the Bonferroni t test or by Student's paired t test, unpaired t test between groups, or the Mann-Whitney rank-sum test. Statistical significance was achieved with a value of PϽ0.05.
Results

Control Group
After 12 weeks of the high-cholesterol diet, total cholesterol significantly increased (the Table) . This was associated with a significant increase in HDL and LDL, whereas triglycerides did not change significantly. In this group after 12 weeks, there was an increase in mean arterial blood pressure (99Ϯ6 mm Hg versus 134Ϯ5 mm Hg, PϽ0.05). This increase in mean arterial blood pressure occurs with the increasing size of the animal and regardless of whether the pigs were fed the normal diet or the high-cholesterol diet. 6 In epicardial coronary vessels removed from the hypercholesterolemic pigs, the in vitro response to bradykinin was attenuated compared with that in the normal-diet pigs (maximal relaxation 70.80Ϯ6.22% versus 88.66Ϯ2.26%, respectively; PϽ0.05; Figure 1 ). There was no difference in the epicardial vessels from the high-cholesterol diet pigs compared with vessels from normal-diet pigs in their response to endothelin-1 (normal endothelin-1 precontraction 11.09Ϯ0.79 g tension, group 1 endothelin-1 precontraction 8.67Ϯ0.86 g tension; Pϭ0.06) or KCl (data not shown). Additionally, preincubation of the vessels with L-NMMA did not alter the magnitude of the precontraction with endothelin-1 (with L-NMMA 9.62Ϯ1.37 g tension versus without L-NMMA 11.09Ϯ0.79 g tension; Pϭ0.42). The endothelium-dependent coronary vasorelaxation in response to the maximal dose of bradykinin (10 Ϫ6 mol/L) was significantly attenuated in the hypercholesterolemic, porcine epicardial vessels (nϭ9 rings) compared with the normal vessels (nϭ7 rings). L-NMMA significantly attenuated the response to bradykinin in the normal vessels (maximal relaxation: 38.66Ϯ6.47% with L-NMMA versus 88.66Ϯ2.26% without L-NMMA; PϽ0.001) and in the high-cholesterol vessels (maximal relaxation: 59.78Ϯ13.49% with L-NMMA versus 70.80Ϯ6.22% without L-NMMA; Pϭ0.022). Endotheliumindependent vasorelaxation to sodium nitroprusside (10 Ϫ9 to 10 Ϫ4 mol/L) was not attenuated with the high-cholesterol diet (maximal relaxation: normal diet 75.79Ϯ4.54%, group 1 75.00Ϯ6.78%). The response of the epicardial vessels to cumulative concentrations of endothelin-1 was not altered in rings from pigs fed the high-cholesterol diet compared with the control rings from pigs on the normal diet (maximal contraction compared with 60 mmol/L KCl in the normal vessels: 131.14Ϯ12.84%, group 1: 116.78Ϯ9.01%; Pϭ0.378). The in vitro arteriolar response to bradykinin at the higher concentrations (10 Ϫ7.5 to 10 Ϫ6 mol/L, Figure 2 ) similarly showed an attenuated endothelium-dependent relaxation in the high-cholesterol pigs (nϭ6 rings) compared with the normal-diet pigs (nϭ7 rings). The arteriolar response to bradykinin was again significantly attenuated with the addition of L-NMMA in arterioles from normal-diet pigs (78.42Ϯ4.08% with L-NMMA versus 96.57Ϯ1.34% without L-NMMA; PϽ0.001).
In group 1, plasma NO x values significantly decreased after 12 weeks of the high-cholesterol diet compared with baseline (Pϭ0.01; the Table) . This decrement was associated with an overall decrease in immunoreactivity for NOS in coronary vessels after 12 weeks of the high-cholesterol diet compared with pigs on the normal diet (2.8Ϯ0.1 versus 1.2Ϯ0.4; PϽ0.01; Figure 3 ). Plasma F 2 -isoprostane levels significantly increased in the control group after 12 weeks of the high-cholesterol diet (the Table) . In previous studies in our laboratory, normal-diet pigs have been shown to not have alterations in plasma F 2 -isoprostane levels after 12 weeks.
Endothelin Receptor Antagonist Groups
After 12 weeks of the high-cholesterol diet, total cholesterol significantly increased in both of the endothelin receptor antagonist groups compared with baseline. There was no difference in cholesterol levels (total cholesterol, HDL, or LDL) between the 3 groups at baseline and after 12 weeks. Additionally, the lipid profile in the normal-diet control group used for the organ chamber experiments was similar to all 3 groups at baseline (total cholesterol 83.6Ϯ7.15 mg/dL). In 
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both group 2, treated with the combined ET-A/ET-B receptor antagonist, and group 3, treated with the selective ET-A receptor antagonist, the normal increase in blood pressure seen in the control group was attenuated (104Ϯ6 mm Hg and 108Ϯ2 mm Hg, respectively, compared with 134Ϯ5 mm Hg in group 1). There was no difference in the response of the epicardial vessels in any of the groups to endothelin-1 (group 2 endothelin-1 precontraction 8.40Ϯ1.48 g tension; Pϭ0.87 versus group 1; group 3 endothelin-1 precontraction 11.33Ϯ0.98 g tension; Pϭ0.07 versus group 1) or KCl (data not shown). The attenuated endothelium-dependent vasorelaxation of the hypercholesterolemic epicardial vessels was normalized when either the combined ET-A/ET-B receptor antagonist (nϭ6, group 2) or the selective ET-A receptor antagonist (nϭ6, group 3) (maximal relaxation 93.25Ϯ4.94% and 86.50Ϯ4.67%, respectively) was given chronically in combination with the high-cholesterol diet (Figure 1 ). The in vitro arteriolar studies (mean size of the vessel was 392Ϯ17 m) showed a similar trend as observed in the epicardial vessels. The attenuated endothelium-dependent relaxation to bradykinin in the high-cholesterol pigs was normalized in both the combined ET-A/ET-B receptor antagonist group (nϭ8) and in the selective ET-A receptor antagonist group (nϭ7, Figure 2) .
After 12 weeks, the decrease in plasma NO x observed in the control group was significantly attenuated in both group 2 and group 3 ( Figure 4) . Similarly, there was an increase in the presence of enzyme immunoreactivity for endothelial NOS in the coronary arteries obtained from the endothelin antagonist groups (groups 2 and 3, 2.1Ϯ0.3 and 2.3Ϯ0.3) compared with the group on the high-cholesterol diet alone (group 1, 1.2Ϯ0.4; Figure 3 ).
Compared with group 1, chronic endothelin receptor antagonism also significantly attenuated the increase in plasma F 2 -isoprostanes from baseline in both the combined endothelin receptor antagonist group, from 108.0Ϯ9.7 to 158.4Ϯ15.9 pg/mL at 12 weeks, and the selective ET-A Figure 2 . Comparison of the relaxation response to cumulative concentrations of bradykinin after precontraction with endothelin-1 in coronary arterioles from pigs on a normal diet (nϭ7), a high-cholesterol diet (nϭ6), or a highcholesterol diet in combination with either a combined ET-A/ET-B receptor antagonist (nϭ8) or a selective ET-A receptor antagonist (nϭ7). *Significant difference between the normal, combined ET-A/ET-B receptor antagonist, and selective ET-A receptor antagonist groups compared with the vessels from pigs on the highcholesterol diet alone. **Significant difference between the normal and selective ET-A receptor antagonist groups compared with the vessels from pigs on the high-cholesterol diet alone. 
Discussion
The current study demonstrates that chronic endothelin receptor antagonism in porcine experimental hypercholesterolemia, by either the combined ET-A/ET-B receptor antagonist or the selective ET-A receptor antagonist, normalizes coronary epicardial and arteriolar endothelial function. This was associated with increased plasma NO x and increased coronary immunoreactivity for constitutive NOS. Finally, these data show that chronic endothelin receptor antagonism attenuates the increase in F 2 -isoprostanes in porcine hypercholesterolemia. This study supports a role for endothelin in the progression of coronary atherosclerosis in experimental porcine hypercholesterolemia.
Endothelin-1 is a potent vasoconstrictor and atherogenic peptide with enhanced immunoreactivity in atherosclerotic tissue. 1, 29, 30 Furthermore, increased endothelin-1 is associated with most atherosclerotic risk factors. 8, 31 Thus, this peptide may be part of a common mechanism in the evolution of coronary atherosclerosis. In atherosclerosis, endothelin-1 alters vascular remodeling by inhibiting apoptosis, promoting proliferation of smooth muscle cells and fibroblasts, and acting as a chemoattractant factor and activator of macrophages. 32, 33 In addition to its direct atherosclerotic effects, endothelin-1 may in part mediate its effects through decreased NO production. NO antagonizes both the atherogenic and vasoconstricting effects of endothelin-1. 34, 35 Furthermore, the regulatory mechanisms of these vasoactive factors interact. NO decreases both the production and the release of endothelin-1 from the vascular endothelium. 36, 37 Endothelin-1 in turn modulates NO production through inhibition of NOS. 38 NO also modulates both the number and affinity of ET-A receptors. 39 In disease states such as hypercholesterolemia and atherosclerosis, an imbalance between NO and endothelin-1 activity is detected and may contribute to both vasomotor abnormalities and vascular remodeling. 1 Thus, determining the effect of chronic endothelin receptor antagonism on NO may demonstrate a mechanism for the antiatherosclerotic effect.
Our study demonstrates that in hypercholesterolemia, chronic endothelin receptor antagonism partly preserves the metabolic products of NO, as determined by total NO x , suggesting that the amount of NO produced is partly preserved. This was associated with an attenuated decrease in coronary endothelial NOS immunoreactivity and preserved coronary endothelial function. The response to bradykinin was similar between the high-cholesterol group and the normal group with L-NMMA, suggesting that the attenuated response in the high-cholesterol group may be due to decreased NO bioavailability in the epicardial vessels and arterioles. Thus, this suggests that preservation of bradykininstimulated vascular relaxation in the endothelin antagonist groups is also associated with preserved agonist-stimulated NO release. We have recently demonstrated that experimental hypercholesterolemia is characterized by enhanced coronary vasoconstriction to endothelin-1 in vivo without a change in endothelin receptor density. 6 This was associated with a decrease in endogenous coronary NO activity. 6 Therefore, preservation of NO production could potently attenuate the enhanced vasoconstrictor effects of endothelin-1. Furthermore, endothelial function has been proposed as a marker for early atherosclerosis. 40 These data suggest that 1 of the mechanisms for the antiatherosclerotic effects of chronic endothelin receptor antagonism may be through the effects on NO.
Besides increased endothelin-1, experimental hypercholesterolemia is also associated with increased vascular production of oxygen free radicals. This leads to augmented oxidation of LDL, which appears to be pivotal in the formation and progression of atherosclerosis through multiple pathways, including enhanced cellular LDL uptake and proinflammatory effects. 12, 13, 41, 42 Oxidative stress also promotes atherosclerosis by increasing endothelin-1 production and inactivation of NO by oxygen free radicals. 14, 17, 18 However, through the same scavenger mechanism, NO can inhibit lipid peroxidation and the formation of F 2 -isoprostanes. 43 Moreover, endothelin may increase oxidative stress by increasing oxygen free-radical formation from macrophages. 19 Thus, oxida- tive stress promotes an atherogenic environment of increased endothelin-1, decreased NO, and increased lipid peroxidation. In addition to the atherosclerotic effects, oxidative stress can also alter vascular tone. In part, this effect may be mediated through the alteration in the balance of NO and endothelin-1. Thus, oxidative stress increases the atherosclerotic process and increases vascular tone.
Our study demonstrates that in hypercholesterolemia, chronic inhibition of endothelin receptors by either combined ET-A/ET-B receptor antagonism or by selective ET-A receptor antagonism attenuates the increase in circulating F 2 -isoprostane concentrations, an in vivo marker of endogenous lipid peroxidation. This suggests that not only may oxidative stress alter endothelin-1 production but also that endothelin-1 may alter oxidative stress. Furthermore, decreased oxidative stress with subsequent increased NO bioavailability and decreased lipid peroxidation may be 1 of the mechanisms for the antiatherosclerotic effects of endothelin receptor antagonists. In addition, this study shows that decreased oxidative stress is associated with normalization of bradykininstimulated endothelium-dependent vasodilatation in vitro. This effect may in part be due to preservation of NO production and decreased formation of vasoconstricting substances, including F 2 -isoprostanes. Despite this potential mechanism, we cannot rule out the possibility that the chronic hemodynamic effects of endothelin receptor antagonism may in part mediate some of these effects. Chronic endothelin antagonists lower blood pressure in both normal-diet pigs and, in the current study, in pigs fed a high-cholesterol diet. 22 The improvement in endothelial function seen with chronic endothelin antagonists is unlikely to be due to acute hemodynamic effects of endothelin receptor antagonism, since we have previously demonstrated that acute endothelin receptor antagonism does not attenuate hypercholesterolemia-induced endothelial dysfunction. 9 Furthermore, this study demonstrated that acute endothelin receptor antagonism does not alter endothelial function in normal-diet pigs.
To determine the relative importance of each receptor type in the hypercholesterolemic state, this study used both a combined ET-A/ET-B receptor antagonist and a selective ET-A receptor antagonist. Because the ET-B receptor is functionally coupled to NOS, one could speculate that blockade of this receptor might be deleterious. However, we and others have previously demonstrated that in pathophysiological states, the ET-B receptor predominantly mediates vasoconstriction. 7, 44, 45 In our current study, blockade of the ET-B receptor as part of the combined ET-A/ET-B receptor blockade showed similar effects as blockade of the ET-A receptor alone. Thus, this study did not show any added benefit of ET-B receptor antagonism in hypercholesterolemia.
In summary, the present study demonstrates that chronic endothelin receptor antagonism in experimental hypercholesterolemia can preserve coronary endothelial function, augment NO production, and decrease oxidative stress. These data support a role of endothelin-1 in the regulation of NO production and suggest a possible therapeutic role for endothelin receptor antagonists in pathophysiological states.
